Pre-clinical heterotopic intrathoracic heart xenotransplantation: A possibly useful clinical technique

Xenotransplantation

Volumn 22, Issue 6, 2015, Pages 427-442

  Abicht, Jan Michael ^a,b   Mayr, Tanja ^a,b   Reichart, Bruno ^b   Buchholz, Stefan ^a   Werner, Fabian ^a   Lutzmann, Isabelle ^a   Schmoeckel, Michael ^a,c   Bauer, Andreas ^a   Thormann, Michael ^a   Langenmayer, Martin ^a   Herbach, Nadja ^a   Pohla, Heike ^a   Herzog, Rudolf ^b   McGregor, Christopher G A ^d,e   Ayares, David ^f   Wolf, Eckhard ^a   Klymiuk, Nikolai ^a   Baehr, Andrea ^a   Kind, Alexander ^g   Hagl, Christian ^a   Ganswindt, Ute ^a   Belka, Claus ^a   Guethoff, Sonja ^a,b   Brenner, Paolo ^a,b   more..

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c DEPARTMENT OF CARDIOLOGY   (Germany)

^d MAYO CLINIC   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f REVIVICOR INC   (United States)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

heart transplantation; heterotopic; intrathoracic; pre clinical; total thoracic and abdominal lymphoid irradiation; xenotransplantation

Indexed keywords

BORTEZOMIB; CD20 ANTIBODY; HLA E ANTIGEN; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PROTEASOME INHIBITOR; TACROLIMUS; THROMBOMODULIN; THYMOCYTE ANTIBODY; ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPERGILLUS; AUTOPSY; BABOON; CONTROLLED STUDY; DISEASE SEVERITY; EXTRACORPOREAL CIRCULATION; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE WALL; HEART VENTRICLE FIBRILLATION; HETEROTOPIC INTRATHORACIC HEART XENOTRANSPLANTATION; IMMUNOADSORPTION; IMMUNOGLOBULIN PRODUCING CELL; LUNG EDEMA; LYMPH NODE IRRADIATION; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; NONHUMAN; ORGAN DONOR; PERIOPERATIVE PERIOD; PIG; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RADIATION DOSE; SEPSIS; SURGICAL TECHNIQUE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSGENIC ANIMAL; XENOTRANSPLANTATION; ANIMAL; HEART TRANSPLANTATION; IMMUNOLOGY; PROCEDURES; XENOGRAFT;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; SWINE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84950258509     PISSN: 0908665X     EISSN: 13993089     Source Type: Journal    
DOI: 10.1111/xen.12213     Document Type: Article

References (63)

1. Cooper DK, Keogh AM, Brink J, et al., Report of the Xenotransplantation Advisory Committee of the International Society for Heart and Lung Transplantation: the present status of xenotransplantation and its potential role in the treatment of end-stage cardiac and pulmonary diseases. J Heart Lung Transplant 2000; 19: 1125-1165.
2. Schmoeckel M, Bhatti FN, Zaidi A, et al., Orthotopic heart transplantation in a transgenic pig-to-primate model. Transplantation 1998; 65: 1570-1577.
3. Vial CM, Ostlie DJ, Bhatti FN, et al., Life supporting function for over one month of a transgenic porcine heart in a baboon. J Heart Lung Transplant 2000; 19: 224-229.
4. Brandl U, Michel S, Erhardt M, et al., Administration of GAS914 in an orthotopic pig-to-baboon heart transplantation model. Xenotransplantation 2005; 12: 134-141.
5. Brenner P, Schmoeckel M, Wimmer C, et al., Mean xenograft survival of 14.6 days in a small group of hDAF-transgenic pig hearts transplanted orthotopically into baboons. Transplant Proc 2005; 37: 472-476.
6. Byrne GW, McGregor CG,. Cardiac xenotransplantation: progress and challenges. Curr Opin Organ Transplant 2012; 17: 148-154.
7. Barnard CN, Losman JG, Curcio CA, et al., The advantage of heterotopic cardiac transplantation over orthotopic cardiac transplantation in the management of severe acute rejection. J Thorac Cardiovasc Surg 1977; 74: 918-924.
8. Novitzky D, Cooper DK, Lanza RP, Barnard CN,. Further cardiac transplant procedures in patients with heterotopic heart transplants. Ann Thorac Surg 1985; 39: 149-154.
9. Cooper DK, Novitzky D, Becerra E, Reichart B,. Are there indications for heterotopic heart transplantation in 1986? A 2- to 11-year follow-up of 49 consecutive patients undergoing heterotopic heart transplantation. Thorac Cardiovasc Surg 1986; 34: 300-304.
10. Reichenspurner H, Odell JA, Cooper DK, et al., Twenty years of heart transplantation at Groote Schuur Hospital. J Heart Transplant 1987; 6: 317-323.
11. Hildebrandt A, Reichenspurner H, Gordon GD, et al., Heterotopic heart transplantation: mid-term hemodynamic and echocardiographic analysis-the concern of arteriovenous-valve incompetence. J Heart Transplant 1990; 9: 675-681; discussion 682.
12. Barnard CN, Wolpowitz A, Losman JG,. Heterotopic cardiac transplantation with a xenograft for assistance of the left heart in cardiogenic shock after cardiopulmonary bypass. S Afr Med J 1977; 52: 1035-1038.
13. Bauer A, Postrach J, Thormann M, et al., First experience with heterotopic thoracic pig-to-baboon cardiac xenotransplantation. Xenotransplantation 2010; 17: 243-249.
14. Palumbo A, Anderson K,. Multiple myeloma. N Engl J Med 2011; 364: 1046-1060.
15. Strober S, Modry DL, Hoppe RT, et al., Induction of specific unresponsiveness to heart allografts in mongrel dogs treated with total lymphoid irradiation and antithymocyte globulin. J Immunol 1984; 132: 1013-1018.
16. Evans MA, Schomberg PJ, Rodeheffer RJ, et al., Total lymphoid irradiation: a novel and successful therapy for resistant cardiac allograft rejection. Mayo Clin Proc 1992; 67: 785-790.
17. Heinzelmann F, Lang PJ, Ottinger H, et al., Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation. Int J Radiat Onc Biol Phys 2008; 70: 523-528.
18. Ghadjar P, Joos D, Martinelli M, et al., Tailored total lymphoid irradiation in heart transplant patients: 10-years experience of one center. Radiat Oncol 2010; 5: 3.
19. Mohiuddin MM, Singh AK, Corcoran PC, et al., Genetically engineered pigs and target-specific immunomodulation provide significant graft survival and hope for clinical cardiac xenotransplantation. J Thorac Cardiovasc Surg 2014; 148: 1106-1113; discussion 1113-1114.
20. Mohiuddin MM, Singh AK, Corcoran PC, et al., Role of anti-CD40 antibody-mediated costimulation blockade on non-Gal antibody production and heterotopic cardiac xenograft survival in a GTKO.hCD46Tg pig-to-baboon model. Xenotransplantation 2014; 21: 35-45.
21. Mohiuddin MM, Singh AK, Corcoran PC, et al., One-year heterotopic cardiac xenograft survival in a pig to baboon model. Am J Transplant 2014; 14: 488-489.
22. Wuensch A, Baehr A, Bongoni AK, et al., Regulatory sequences of the porcine THBD gene facilitate endothelial-specific expression of bioactive human thrombomodulin in single- and multitransgenic pigs. Transplantation 2014; 97: 138-147.
23. Garber JC, Barbee RW, Bielitzki JT, et al., Guide for the Care and Use of Laboratory Animals, published by the US National Institutes of Health (Eighth Edition). Washington, DC: The National Academy Press, 2011.
24. Bretschneider HJ, Hubner G, Knoll D, et al., Myocardial resistance and tolerance to ischemia: physiological and biochemical basis. J Cardiovasc Surg (Torino) 1975; 16: 241-260.
25. Holscher M, Groenewoud AF,. Current status of the HTK solution of Bretschneider in organ preservation. Transplant Proc 1991; 23: 2334-2337.
26. Novitzky D, Cooper DK, Barnard CN,. The surgical technique of heterotopic heart transplantation. Ann Thorac Surg 1983; 36: 476-482.
27. Brenner P, Schmoeckel M, Wimmer C, et al., Combination of hDAF-transgenic pig hearts and immunoadsorption in heterotopic xenotransplantation of immunosuppressed baboons. Transplant Proc 2005; 37: 483-486.
28. McGregor CG, Davies WR, Oi K, et al., Cardiac xenotransplantation: recent preclinical progress with 3-month median survival. J Thorac Cardiovasc Surg 2005; 130: 844-851.
29. Schmidt M, Winther KD, Secher JO, Callesen H,. Postmortem findings in cloned and transgenic piglets dead before weaning. Theriogenology 2015; 84: 1014-1023.
30. Li G, Jia Q, Zhao J, et al., Dysregulation of genome-wide gene expression and DNA methylation in abnormal cloned piglets. BMC Genom 2014; 15: 811.
31. Shen CJ, Tsou YA, Chen HL, et al., Osteoponin promoter controlled by DNA methylation: aberrant methylation in cloned porcine genome. Biomed Res Int 2014; 2014: 1-16 Article 327538.
32. Novitzky D, Cooper DKC, Brink JG, Reichart BA,. Sequential-second and third-transplants in patients with heterotopic heart allografts. Clin Transplant 1987; 1: 57-62.
33. Levin B, Bohannon L, Warvariv V, Bry W, Collins G,. Total lymphoid irradiation (TLI) in the cyclosporine era-use of TLI in resistant cardiac allograft rejection. Transplant Proc 1989; 21: 1793-1795.
34. Frist WH, Winterland AW, Gerhardt EB, et al., Total lymphoid irradiation in heart transplantation: adjunctive treatment for recurrent rejection. Ann Thorac Surg 1989; 48: 863-864.
35. Macoviak JADJ, Simmons J, Givan D, Nunes N, Lawrinson W,. Low dose total lymphoid irradiation for recalcitrant myocardial rejection. J Heart Transplant 1990; 9: 76.
36. Hunt SA, Strober S, Hoppe RT, Stinson EB,. Total lymphoid irradiation for treatment of intractable cardiac allograft rejection. J Heart Lung Transplant 1991; 10: 211-216.
37. Salter MM, Kirklin JK, Bourge RC, et al., Total lymphoid irradiation in the treatment of early or recurrent heart rejection. J Heart Lung Transplant 1992; 11: 902-911; discussion 11-12.
38. Kirklin JK, George JF, McGiffin DC, et al., Total lymphoid irradiation: is there a role in pediatric heart transplantation? J Heart Lung Transplant 1993; 12: S293-S300.
39. Salter SP, Salter MM, Kirklin JK, Bourge RC, Naftel DC,. Total lymphoid irradiation in the treatment of early or recurrent heart transplant rejection. Int J Radiat Oncol Biol Phys 1995; 33: 83-88.
40. Keogh A, Morgan G, Macdonald P, et al., Clinical heart transplantation. Total lymphoid irradiation for resistant rejection after heart transplantation: only moderate success medium-term. J Heart Lung Transplant 1996; 15: 231-233.
41. Madden BP, Backhouse L, McClosky D, et al., Total lymphoid irradiation as rescue therapy after heart transplantation. J Heart Lung Transplant 1996; 15: 234-238.
42. Wolden SL, Tate DJ, Hunt SA, Strober S, Hoppe RT,. Long-term results of total lymphoid irradiation in the treatment of cardiac allograft rejection. Int J Radiat Oncol Biol Phys 1997; 39: 953-960.
43. Ross HJ, Gullestad L, Pak J, et al., Methotrexate or total lymphoid radiation for treatment of persistent or recurrent allograft cellular rejection: a comparative study. J Heart Lung Transplant 1997; 16: 179-189.
44. Trachiotis GD, Johnston TS, Vega JD, et al., Single-field total lymphoid irradiation in the treatment of refractory rejection after heart transplantation. J Heart Lung Transplant 1998; 17: 1045-1048.
45. Madden BP, Barros J, Backhouse L, et al., Intermediate term results of total lymphoid irradiation for the treatment of non-specific graft dysfunction after heart transplantation. Eur J Cardiothorac Surg 1999; 15: 663-666.
46. Keogh AM, Arnold RH, Macdonald PS, et al., A randomized trial of tacrolimus (FK506) versus total lymphoid irradiation for the control of repetitive rejection after cardiac transplantation. J Heart Lung Transplant 2001; 20: 1331-1334.
47. Chin C, Hunt S, Robbins R, et al., Long-term follow-up after total lymphoid irradiation in pediatric heart transplant recipients. J Heart Lung Transplant 2002; 21: 667-673.
48. Asano M, Gundry SR, Razzouk AJ, et al., Total lymphoid irradiation for refractory rejection in pediatric heart transplantation. Ann Thorac Surg 2002; 74: 1979-1985.
49. Lim TS, O'Driscoll G, Freund J, et al., Short-course total lymphoid irradiation for refractory cardiac transplantation rejection. J Heart Lung Transplant 2007; 26: 1249-1254.
50. Strober S, Slavin S, Gottlieb M, et al., Allograft tolerance after total lymphoid irradiation (TLI). Immunol Rev 1979; 46: 87-112.
51. Field EH, Becker GC,. The immunosuppressive mechanism of total lymphoid irradiation. I. The effect on IL-2 production and IL-2 receptor expression. Transplantation 1989; 48: 499-505.
52. Smit JA, Stark JH, Myburgh JA,. Mechanisms of immunologic tolerance following total lymphoid irradiation in the baboon. Transplant Proc 1987; 19: 490-492.
53. Myburgh JA, Smit JA, Stark JH,. Transplantation tolerance following total lymphoid irradiation in baboon-to-vervet monkey kidney xenotransplantation. Transplant Proc 1994; 26: 1080-1081.
54. Comerci GD Jr, Williams TM, Kellie S,. Immune tolerance after total lymphoid irradiation for heart transplantation: immunosuppressant-free survival for 8 years. J Heart Lung Transplant 2009; 28: 743-745.
55. Knechtle SJ, Halperin EC, Bollinger RR,. Xenograft survival in two species combinations using total-lymphoid irradiation and cyclosporine. Transplantation 1987; 43: 173-175.
56. Steinbruchel DA, Madsen HH, Nielsen B, et al., Graft survival in a hamster-to-rat heart transplantation model after treatment with total lymphoid irradiation, cyclosporine A, and a monoclonal anti-T-cell antibody. Transplant Proc 1990; 22: 1088.
57. Alqaisi M, DeMasi R, Thomas J, et al., Quantification of parameters of total lymphoid irradiation that produce effective antixenograft rejection. Transplant Proc 1992; 24: 515-516.
58. Panza A, Roslin M, Coons M, et al., Successful cardiac xenogeneic transplantation in primates using total lymphoid irradiation. Eur J Cardiothorac Surg 1991; 5: 161-163.
59. Norin AJ, Roslin MS, Panza A, et al., TLI induces specific B-cell unresponsiveness and long-term monkey heart xenograft survival in cyclosporine-treated baboons. Transplant Proc 1992; 24: 508-510.
60. Roslin MS, Tranbaugh RE, Panza A, et al., One-year monkey heart xenograft survival in cyclosporine-treated baboons. Suppression of the xenoantibody response with total-lymphoid irradiation. Transplantation 1992; 54: 949-955.
61. Patel J, Everly M, Chang D, et al., Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. J Heart Lung Transplant 2011; 30: 1320-1326.
62. Guthoff M, Schmid-Horch B, Weisel KC, et al., Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation. Transplant immunol 2012; 26: 171-175.
63. Lin CC, Ezzelarab M, Shapiro R, et al., Recipient tissue factor expression is associated with consumptive coagulopathy in pig-to-primate kidney xenotransplantation. Am J Transplant 2010; 10: 1556-1568.